Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding

From Medscape Education Diabetes & Endocrinology
Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding CME/CE
Steven V. Edelman, MD Faculty and Disclosures
CME/CE Released: 04/21/2015 ; Valid for credit through 04/21/2016

You may need to Sign Up / Registration ( link below) as a Member to view the 22 minute educational video / material

This basically says that there is no statistical difference in A1c for inhaled vs standard insulin. the tradeoff appears to be faster BG lowering response for all plus a dry cough for about 5% of inhalant users.
Steve Edelman’s use of the word “non-inferior” instead of “no difference” drove me crazy. An unexpected word taking the place of a perfectly understandable traditional word/phrase causes me to have to take time to think “what the heck did he mean by that” and then I lose whatever narrative was coming next. Or perhaps the terminology has changed to express “no difference” since I left the health field.

A 12 unit cartridge strength of AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes. The 12 unit cartridge was approved by the U.S. Food and Drug Administration on April 17, 2015 and is expected to be launched by Sanofi in the second half of 2015.
The new dosage strength complements the existing 4 unit and 8 unit cartridges and will provide patients with another option to receive their prescribed dose.